10320 Camino Santa Fe, Suite G
San Diego, CA 92121
Tel: 858.875.1900 Fax: 858.875.1999

CHC1L Antibody (N-term) Blocking Peptide
Synthetic peptide
Catalog # BP6741a

Specification

CHC1L Antibody (N-term) Blocking Peptide - Product Information

Primary Accession O95199

CHC1L Antibody (N-term) Blocking Peptide - Additional Information

Gene ID 1102

Other Names
RCC1 and BTB domain-containing protein 2, Chromosome condensation 1-like, CHC1-L, RCC1-like G exchanging factor, Regulator of chromosome condensation and BTB domain-containing protein 2, RCBTB2, CHC1L, RLG

Target/Specificity
The synthetic peptide sequence used to generate the antibody AP6741a was selected from the N-term region of human CHC1L. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.

Format
Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

Storage
Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

Precautions
This product is for research use only. Not for use in diagnostic or therapeutic procedures.

CHC1L Antibody (N-term) Blocking Peptide - Protein Information

Name RCBTB2

Synonyms CHC1L, RLG

Cellular Location
Cytoplasmic vesicle, secretory vesicle, acrosome {ECO:0000250|UniProtKB:Q99LJ7}. Note=Mainly found in the acrosomal cap region. {ECO:0000250|UniProtKB:Q99LJ7}

CHC1L Antibody (N-term) Blocking Peptide - Protocols

Provided below are standard protocols that you may find useful for product applications.

- Blocking Peptides

CHC1L Antibody (N-term) Blocking Peptide - Images

CHC1L Antibody (N-term) Blocking Peptide - Background

RCBTB2 is a member of the RCC1-related GEF family. The N-terminal half of the amino acid sequence shows similarity to the regulator of chromosome condensation RCC1, which acts as a guanine nucleotide exchange factor (GEF) protein for the Ras-related GTPase Ran.

CHC1L Antibody (N-term) Blocking Peptide - References

Latil,A., Int. J. Cancer 99 (5), 689-696 (2002)